story of the week
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum/Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study
J Thorac Oncol 2022 Apr 27;[EPub Ahead of Print], A Louw, V Panou, WM Szejniuk, C Meristoudis, SM Chai, C van Vliet, YCG Lee, IM Dick, T Firth, LA Lynggaard, AB Asghari, M Vyberg, J Hansen, J Creaney, OD RøeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.